Park S, Bergmark BA, Shi M, et al. - Researchers studied the interaction between blood pressure and the efficacy and safety of direct oral anticoagulants among 19,679 patients with atrial fibrillation and hypertension enrolled in the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48 trial. The participants were grouped based on average systolic blood pressure (SBP) and diastolic blood pressure (DBP). Patients with elevated average SBP or DBP more frequently suffered a stroke/systemic embolic event. Attenuation in the risk of major bleeding events, including intracranial hemorrhage, was reported in relation to higher dose edoxaban regimen, without modification by average SBP. Across the full range of SBP, consistent efficacy and safety were displayed by edoxaban. In patients with elevated DBP, the superior safety of edoxaban was most noticeable.